ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: PP16

Utilization of My Knee Notes for Enhanced Healthcare Management
Abstract Number: 0001

Type I Interferon and Anifrolumab Effects on Bone Marrow and Blood Plasma Cells in Systemic Lupus Erythematosus
Abstract Number: 0002

Preclinical Evaluation of BCMA And/or CD19 Nanobody-based Single or Compound CAR-T Cells Targeting B and Plasma Cells Associated with Autoimmune Disorders
Abstract Number: 0003

CLN-978, a CD19-directed T Cell Engager (TCE), Leads to Rapid and Deep B Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases
Abstract Number: 0004

Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells
Abstract Number: 0005

Autoantibodies Identified in Myositis-Specific Autoantibody Negative Juvenile Myositis Patients
Abstract Number: 0006

NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Abstract Number: 0007

Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation
Abstract Number: 0008

Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Abstract Number: 0009

Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Abstract Number: 0010

Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells
Abstract Number: 0011

Preclinical Manufacturability and Activity of KYV-102 from Patients with Systemic Lupus Erythematosus Using Ingenui-T: A Rapid, Autologous Chimeric Antigen Receptor T-Cell Manufacturing Solution Utilizing Whole Blood
Abstract Number: 0012

Dichotomous Expression of CXCR3 and CCR9 and Relationship to Intestinal Permeability in B Cells in Rheumatoid Arthritis
Abstract Number: 0013

Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Abstract Number: 0014

Phenotypic Validation of Humanized IgA1 and CD89 Transgenic Mice as a Model for IgA Nephropathy-Like Autoimmune Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].